Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + Chlorambucil vs Rituximab + Chlorambucil vs Chlorambucil in untreated CLL
NCT01010061Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2009
- Primary completion
- Jul 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Roche. Started Dec 2009; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01010061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010061.